A recent report describes the development of a small molecule inhibitor of ACSL4, PRGL493 (N-(4-(3-(5-methylfuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazin-2yl)acetamide) that blocks cell proliferation and tumor growth in both breast and prostate cancer models as well as sensitizing tumor cells to chemotherapeutic and hormonal treatment [82]. This evidence concerns the gene ACSL4 and Familial prostate cancer.